F-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 09 2021 - 9:00AM
F-star Therapeutics, Inc. (NASDAQ:
FSTX), a clinical-stage biopharmaceutical company
dedicated to developing next generation bispecific immunotherapies
to transform the lives of patients with cancer, announced today
that F-star will participate next week at the H. C. Wainwright 23rd
Annual Global Investment Conference, taking place virtually
September 13-15.
F-star CEO Eliot Forster will present, and the
executive team will be conducting one on one meetings during the
conference.
The video webcast of the presentation will be
available online beginning at 7 a.m. on Monday September 13 at this
link or via the F-star website. The webcast replay will be
available for 90 days.
About F-star Therapeutics,
Inc. F-star is a clinical-stage biopharmaceutical
company developing tetravalent bispecific antibodies for a paradigm
shift in cancer therapy. By developing medicines that seek to block
tumor immune evasion, the Company’s goal is to offer patients
greater and more durable benefits than current immuno-oncology
treatments. Through its proprietary tetravalent, bispecific natural
antibody (mAb²™) format, F-star’s mission is to generate highly
differentiated best-in-class drug candidates with monoclonal
antibody-like manufacturability. For more information
visit www.f-star.com and follow us
on LinkedIn and Twitter.
For further information, please
contact:
For investor
inquiries Lindsey Trickett VP
Investor Relations & Communications +1 240 543
7970 lindsey.trickett@f-star.com For
media inquiriesHelen ShikShik
Communications LLC+1 617-510-4373shik.helen10@gmail.com
F star Therapeutics (NASDAQ:FSTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
F star Therapeutics (NASDAQ:FSTX)
Historical Stock Chart
From Sep 2023 to Sep 2024